Assessment of diabetes mellitus type 2 treatment costs in the Republic of Serbia;Procena troškova lečenja diabetes mellitus-a tip 2 u Republici Srbiji

Vojnosanitetski Pregled

Volumn 66, Issue 4, 2009, Pages 271-276

  Biorac, Nenad ^a   Jakovljević, Mihajlo ^b,c   Stefanović, Danka ^a   Perović, Saša ^a   Janković, Slobodan ^b  

^a Dom Zdravlja ^*  (Serbia)

^b Katedra za farmakologiju i toksikologiju   (Serbia)

^c Medicinski Fakultet u Kragujevcu   (Macedonia)

Author keywords

Costs and cost analysis; Diabetes mellitus, type 2; Hipoglycemic agents; Insulin; Yugoslavia

Indexed keywords

ANTIDIABETIC AGENT; INSULIN;

ABSENTEEISM; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST OF ILLNESS; DIABETIC PATIENT; DRUG COST; DRUG USE; DRUG UTILIZATION; EMPLOYEE; HEALTH CARE COST; HEALTH SERVICE; HUMAN; INSULIN TREATMENT; LENGTH OF STAY; MAJOR CLINICAL STUDY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PHYSICAL DISEASE; PREVALENCE; RANDOMIZED CONTROLLED TRIAL; RETIREMENT; SERBIA; TREATMENT DURATION; AGED; ECONOMICS; MIDDLE AGED;

ADULT; AGED; COST OF ILLNESS; DIABETES MELLITUS, TYPE 2; HEALTH CARE COSTS; HUMANS; MIDDLE AGED; SERBIA;

EID: 66349107723     PISSN: 00428450     EISSN: None     Source Type: Journal    
DOI: 10.2298/VSP0904271B     Document Type: Article

References (25)

1. Robert JB. Pharmacoeconomics in Perspective: a Primer on Research, Techniques, and Information. Toronto: Pharmacetical Products Press, Haworth; 1984.
2. Rice DP. Cost of illness studies: what is good about them? Inj Prev 2000; 6(3): 177-179
3. Tarricone R. Cost-of-illness analysis. What room in health economics? Health Policy 2006; 77(1): 51-63.
4. Segel JE. Cost of illness studies - a primer. RTI-UNC Center of Excellencce in Health Promotion Economics. RTI Intrnational; 2006.
5. Byford S, Torgerson DJ, Raftery J. Economic note: cost of illness studies. BMJ 2000; 320(7245): 1335. (Pubitemid 30245728)
6. World Healt Organization. The Word Health Report 2002. Geneva: World Healt Organization; 2003.
7. Preker AS, Carrin G, Dror D, Jakab M, Hsiao W, Arhin-Tenkorang D. Effectiveness of community health financing in meeting the cost of illness. Bull World Health Organ 2002; 80(2): 143-150 (Pubitemid 34205100)
8. Knežević T. Health Statistics Almanac of the Republic of Serbia 2006. Beograd: Institut za javno zdravlje Srbije "dr Milan Jovanović Batut"; 2007.
9. Tuomilehto J, Lindström J, Eriksson JG, Valle TT, Hämäläinen H, Ilanne-Parikka P, et al. Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344(18): 1343-1350
10. Henriksson F, Jönsson B. Diabetes: the cost of illness in Sweden. J Intern Med 1998; 244(6): 461-468 (Pubitemid 28552852)
11. American Diabetes Association. Economic costs of diabetes in the U.S. in 2007. Diabetes Care 2008; 31(3): 596-615.
12. Pohar SL, Johnson JA. Health care utilization and costs in Saskatchewan's registered Indian population with diabetes. BMC Health Serv Res 2007; 7: 126. (Pubitemid 47407723)
13. Grover S, Avasthi A, Bhansali A, Chakrabarti S, Kulhara P. Cost of ambulatory care of diabetes mellitus: a study from north India. Postgrad Med J 2005; 81(956): 391-395 (Pubitemid 40834905)
14. Khowaja LA, Khuwaja AK, Cosgrove P. Cost of diabetes care in out-patient clinics of Karachi, Pakistan. BMC Health Serv Res 2007; 7: 189.
15. Massi-Benedetti M. CODE-2 Advisory Board. The cost of diabetes Type II in Europe: the CODE-2 Study. Diabetologia 2002; 45(7): S1-4.
16. Chale SS, Swai AB, Mujinja PG, McLarty DG. Must diabetes be a fatal disease in Africa? Study of costs of treatment. BMJ 1992; 304(6836): 1215-1218
17. Regulations for drugs prices forming corterion. Služb Glasn 2004; 117. (Serbian)
18. Republički zavod za statistiku. Annual Serbian Statistical Journal. Belgrade: Republički zavod za statistiku 2008. (Serbian)
19. Radonjić V, Cross D signukić Lj. Sales and consumption of humane drugs in the Republic Serbia. Belgrade: Agencija za lekove i medicinska sredstva Srbije; 2005. (Serbian)
20. Radonjić V, Cross D signukić Lj. Sales and consumption of humane drugs in the Republic Serbia. Belgrade: Agencija za lekove i medicinska sredstva Srbije; 2006. (Serbian)
21. Narodna banka Srbije. Report on monetary politics of the National Bank of Serbia for the year 2006. Belgrade: Narodna banka Srbije; 2007. (Serbian)
22. Oglesby AK, Secnik K, Barron J, Al-Zakwani I, Lage MJ. The association between diabetes related medical costs and glycemic control: a retrospective analysis. Cost Eff Resour Alloc 2006; 4: 1. (Pubitemid 43264496)
23. Valdmanis V, Smith DW, Page MR. Productivity and economic burden associated with diabetes. Am J Public Health 2001; 91(1): 129-130 (Pubitemid 32049281)
24. Ng YC, Jacobs P, Johnson JA. Productivity losses associated with diabetes in the US. Diabetes Care 2001; 24(2): 257-261 (Pubitemid 32119121)
25. Budget Low of the Republic of Serbia. Služb glasn 2007; 58. (Serbian)